Ｖａｎｃｏｍｙｃｉｎ‐ｒｅｓｉｓｔａｎｔｅｎｔ　ｅｎｔｅｒｏｃｏｃｃｉ（ＶＲＥ）に対する抗菌化学療法　　リネゾリドを中心に

DOI 機関リポジトリ HANDLE 被引用文献6件 参考文献53件
  • 柳原 克紀
    長崎大学医学部第二内科 長崎大学大学院医歯薬学総合研究科薬物治療学
  • 河野 茂
    長崎大学医学部第二内科 長崎大学大学院感染分子病態学

書誌事項

タイトル別名
  • Antimicrobial agents against vancomycin-resistant enterococci (Linezolid).
  • Resistant enterococci (Linezolid)mycin
  • リネゾリドを中心に

この論文をさがす

抄録

Oxazolidinones are a new class of antimicrobials with a unique mechanism of action. This class of bacterial protein synthesis inhibitors functions by binding to the 50 S ribosomal subunit and preventing formation of a functional initiation complex in bacterial translation systems.Linezolid (LZD), an oxazolidinone anti-bacterial agent with a mechanism of action distinct from those of conventional antibacterial agents, was recently developed and its effectiveness against methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-insensitive S. aureus (VISA) highly anticipated. LZD has been approved as a new antibiotic against infections with gram-positive organisms by many countries, including the United States. Aclinical trial with LZD against MRSA infection hes been done in Japan.

収録刊行物

被引用文献 (6)*注記

もっと見る

参考文献 (53)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ